Biologics and new modalities have dominated recent pharmaceutical developments, but small molecule drugs are making a significant comeback. These drugs are designed to penetrate cell membranes and target cancer cells with unprecedented precision. Their ability to disrupt intracellular processes offers new hope for cancer treatment strategies. https://hubs.li/Q02H-VBb0 #Oncology #CancerResearch #DrugDevelopment
Laboratory Testing Division, Drug Discovery and Development
Pharmaceutical Manufacturing
Plainsboro, NJ 2,196 followers
Supporting customers across the full spectrum of their development efforts to deliver innovative medicines to patients.
About us
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated. Our state-of-the-art Laboratory Testing Division in New Jersey provides leading bioanalytical & drug metabolism contract research services to a global customer base of pharmaceutical, biotech & agrochemical firms. Our bioanalytical services support a wide range of compounds-small & large molecules, new modalities including oligonucleotides, ADC, bispecific antibodies & more-from discovery to preclinical IND-enabling & regulated clinical studies. Capabilities include LC-MS/MS & immunochemistry platforms for GLP & non-GLP & customized Central Laboratory services to facilitate global clinical studies. Our comprehensive drug metabolism services are tailored to support the entire drug development cycle, from early discovery through IND-enabling to late-stage clinical development. Capabilities include in vivo pharmacokinetics, in vitro ADME, in vitro & in vivo biotransformation, & non-clinical radiolabel ADME (mass balance & QWBA).
- Website
-
https://labtesting.wuxiapptec.com/
External link for Laboratory Testing Division, Drug Discovery and Development
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001 employees
- Headquarters
- Plainsboro, NJ
- Specialties
- DMPK, Bioanalysis, Toxicology, Preclinical Testing, Clinical Testing, Medical Device, Laboratory Testing, CMC Analytical Services, and Regulatory Services
Updates
-
Effective antibody-drug conjugates (ADCs) hinge on understanding their intricate dynamics. This is where LC-MS/MS shines. Unlike Ligand Binding Assays (LBAs), LC-MS/MS offers unparalleled precision, capturing bound and unbound cytotoxins. Discover how this technique enables precise quantification of ADC components, driving the development of these life-saving therapies. Dive in and learn how we’re enhancing the future of cancer treatment! #CancerResearch #LCMS #ADCs #Biotechnology https://hubs.li/Q02GdmST0
The Advantages of LC-MS/MS in Optimizing ADC Bioassays
-
Our latest blog delves into the critical role of protein biomarkers in bioanalysis and pharmaceutical research. From understanding their classifications to leveraging advanced detection technologies, gain insights to navigate the complexities of biomarker-based bioanalysis. Learn more about the categories and roles of biomarkers, innovative detection technologies, and how to address bioanalytical challenges. Empower your research and development efforts with the knowledge of biomarker applications. #Bioanalysis #PharmaceuticalResearch #ProteinBiomarkers #BiotechInnovation https://hubs.li/Q02CJgFX0
Application of Protein Biomarkers in Pharmaceutical Research and Bioanalysis Strategies
https://labtesting.wuxiapptec.com
-
Maximizing the potential of oligonucleotides in treating genetic disorders and cancers requires a deep dive into their stability profiles. Our newest blog post presents insights into oligo degradation rates and stability. This advancement helps predict pharmacokinetic behavior, guiding the design and optimization of oligo-based therapeutics. Explore how this assay is enhancing drug development processes for better patient outcomes. https://hubs.li/Q02C56_z0 #DrugDiscovery #Oligonucleotide #PrecisionMedicine #InVitro #Assay #DMPK #ADME
-
-
Before any new drug can be tested in humans, extensive safety studies are conducted to determine the drug's toxicity at various doses and over different periods. The data gathered from these studies is critical. It helps establish the safe starting dosage for clinical trials and outlines the necessary parameters to monitor for potential side effects. As our understanding of drug interactions and human biology becomes more complex, the role of efficient and comprehensive toxicology studies becomes even more pivotal. What does the future hold for toxicity testing?https://hubs.ly/Q02D4CNt0 #DrugDiscovery #Pharmaceuticals #Toxicology #PatientSafety #ClinicalTrials
The Vital Role of Toxicity Studies in New Drug Development
https://labtesting.wuxiapptec.com
-
Radionuclide Drug Conjugates (RDCs) represent a paradigm shift in oncology, offering the dual benefits of precise tumor targeting and diagnostic capabilities, all while minimizing the side effects typically associated with cancer treatment. As more RDCs enter clinical trials and the pipeline for approval grows, we are on the brink of a new era in cancer care. What are the challenges they face? https://hubs.li/Q02C4Vz00 #OncologyInnovation #nuclearmedicine #radiopharmaceuticals #CancerTreatment #DMPK #drugdiscovery #drugdevelopment
Radionuclide Drug Conjugates: Pioneering targeted cancer therapy
https://www.drugdiscoverytrends.com
-
Toxicology studies are effective, but only when paired with the right safety assessment team. These six toxicology studies (and an experienced, full-scale testing partner) can make all the difference. https://hubs.li/Q02w5hkp0
6 Types of Toxicology Studies for IND & NDA Programs
https://labtesting.wuxiapptec.com
-
The clock is ticking towards the 2026 USP deadline. With no products grandfathered in, it's essential to act now to avoid backlogs and ensure your products meet new standards. Partnering with the right lab can make all the difference. Start planning today for budget management and regulatory compliance tomorrow. https://hubs.li/Q02z3RM40 #biopharma #USP665 #regulatorycompliance #singleusesystems
-
-
Ensuring the integrity of medication and vaccines is non-negotiable. This blog post explains how Container Closure Integrity Testing (CCIT) is critical in the lifecycle of biopharmaceutical products. Get insights into the technologies and partnerships driving this essential quality assurance process. https://hubs.ly/Q02zhWHp0 #CCIT #biopharma #drugsafety
-
-
The IND and NDA stages of the regulatory journey are not merely hurdles but opportunities for developers and sponsors to ensure their innovative treatments meet the highest safety and efficacy standards. However, these applications represent potential bottlenecks that can cost developers dearly in both time and resources. How can drug sponsors ensure they avoid the potential pitfalls and bring therapies to patients efficiently and safely?https://hubs.li/Q02vqTbr0 #NDA #IND #Innovation #Drugdevelopment
Navigating the Path from IND to NDA
https://labtesting.wuxiapptec.com